

Albireo Pharma Inc (ALBO) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/AFD8536CDFBEN.html>

Date: September 2021

Pages: 49

Price: US\$ 125.00 (Single User License)

ID: AFD8536CDFBEN

Abstracts

Albireo Pharma Inc (ALBO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Albireo Pharma Inc (Albireo), formerly Biodel Inc, focuses on the development and commercialization of novel bile acid modulators for treatment of orphan pediatric liver diseases, gastrointestinal (GI) disorders and other diseases. Its pipeline products include odevixibat (A4250) intended for treatment of progressive familial intrahepatic cholestasis (PFIC), biliary atresia, alagille syndrome and other cholestaticc; A3384 for bile acid malabsorption; and elobixibat for nonalcoholic steatohepatitis (NASH). Elobixibat is approved in Japan for the treatment of chronic constipation. The company is investigating bile acid modulator for nonalcoholic steatohepatitis (NASH) and other preclinical trials for the treatment of adult liver diseases. It operates in the US, the UK, and Sweden. Albireo is headquartered in Boston, Massachusetts, the US.

Albireo Pharma Inc Key Recent Developments

Sep 08,2021: Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Aug 05,2021: Albireo Reports Q2 Financial Results and Business Update
Jun 30,2021: Albireo to Report Second Quarter 2021 Financial Results on August 5
Jun 24,2021: Albireo to Present at Piper Sandler's Virtual EASL Takeaway Day
May 06,2021: Albireo Reports Q1 Financial Results and Business Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios

and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Albireo Pharma Inc - Key Facts
Albireo Pharma Inc - Key Employees
Albireo Pharma Inc - Key Employee Biographies
Albireo Pharma Inc - Major Products and Services
Albireo Pharma Inc - History
Albireo Pharma Inc - Company Statement
Albireo Pharma Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Albireo Pharma Inc - Business Description
R&D Overview
Albireo Pharma Inc - Corporate Strategy
Albireo Pharma Inc - SWOT Analysis
SWOT Analysis - Overview
Albireo Pharma Inc - Strengths
Albireo Pharma Inc - Weaknesses
Albireo Pharma Inc - Opportunities
Albireo Pharma Inc - Threats
Albireo Pharma Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Albireo Pharma Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 05, 2021: Albireo Reports Q2 Financial Results and Business Update
Jun 30, 2021: Albireo to Report Second Quarter 2021 Financial Results on August
Jun 24, 2021: Albireo to Present at Piper Sandler’s Virtual EASL Takeaway Day
May 06, 2021: Albireo Reports Q1 Financial Results and Business Update
Apr 13, 2021: Albireo Expands Leadership with Joan Connolly as Chief Technology Officer
Apr 06, 2021: Albireo to Participate in the Needham 20th Annual Virtual Healthcare Conference
Feb 25, 2021: Albireo reports Q4 and year-end 2020 financial results and business update
Feb 23, 2021: Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences
Feb 18, 2021: Albireo to Report Q4 and Year-End 2020 Financial Results on February
Jan 05, 2021: Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Albireo Pharma Inc, Key Facts
Albireo Pharma Inc, Key Employees
Albireo Pharma Inc, Key Employee Biographies
Albireo Pharma Inc, Major Products and Services
Albireo Pharma Inc, History
Albireo Pharma Inc, Subsidiaries
Albireo Pharma Inc, Key Competitors
Albireo Pharma Inc, Ratios based on current share price
Albireo Pharma Inc, Annual Ratios
Albireo Pharma Inc, Annual Ratios (Cont...1)
Albireo Pharma Inc, Interim Ratios
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Albireo Pharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Albireo Pharma Inc, Performance Chart (2016 - 2020)

Albireo Pharma Inc, Ratio Charts

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Albireo Pharma Inc (ALBO) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/AFD8536CDFBEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AFD8536CDFBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970